In a phase I–II study of 252 relapsed/refractory AML patients, gilteritinib was well tolerated, with 37% of FLT3-ITD+ patients achieving composite CR, along with 9% of FLT3 wild-type patients [179]. This evidence concerns the gene FLT3 and acute myeloid leukemia.